# US 2025/0146080 A1 · Methods for overcoming tazemetostat-resistance in cancer patients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0146080 A1
- Document ID: US20250146080A1
- Status: Published application
- Kind: A1
- Application number: 18/838,962
- Filed: 2023-02-16
- Published: 2025-05-08
- Earliest claimed: 2022-02-17
- Applicants: Memorial Sloan-Kettering Cancer Center; Memorial Hospital for Cancer and Allied Diseases; Sloan-Kettering Institute for Cancer Research
- Inventors: Yaniv Kazansky; Alex Kentsis
- Web page: https://patentgrep.com/patent/US20250146080A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- G16H 20/17: delivered via infusion or injection
- G16H 50/70: for mining of medical data, e.g. analysing previous cases of other patients
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- G01N 2333/4703: Regulators; Modulating activity
- G01N 2333/96455: Kallikrein (3.4.21.34; 3.4.21.35)
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G16B 25/10: Gene or protein expression profiling; Expression-ratio estimation or normalisation
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

The present disclosure provides methods for overcoming tazemetostat resistance in patients diagnosed with or suffering from sarcomas. In some embodiments, the methods of the present technology include administering tazemetostat in combination with an ATR inhibitor, a CDK4/6 inhibitor or an AURK inhibitor.

## Claims

### Claim 1

A method for selecting a sarcoma patient for treatment with tazemetostat comprising:
detecting mRNA or polypeptide expression and/or activity levels of KLF4 in a biological sample obtained from the sarcoma patient that are elevated compared to a control sample obtained from a healthy subject or a predetermined threshold; and
administering to the sarcoma patient an effective amount of tazemetostat.

### Claim 2

A method for selecting a sarcoma patient for treatment with tazemetostat and an additional therapeutic agent comprising:
(A)
detecting mRNA or polypeptide expression and/or activity levels of one or more of PRICKLE1, PLK1, and CELSR2 in a biological sample obtained from the sarcoma patient that are elevated compared to a control sample obtained from a healthy subject or a predetermined threshold; and
administering to the sarcoma patient an effective amount of tazemetostat and the additional therapeutic agent, wherein the additional therapeutic agent is an ATR inhibitor, an AURK inhibitor or a CDK4/6 inhibitor; or
(B)
detecting mRNA or polypeptide expression and/or activity levels of KLF4 in a biological sample obtained from the sarcoma patient that are reduced compared to a control sample obtained from a healthy subject or a predetermined threshold; and
administering to the sarcoma patient an effective amount of tazemetostat and the additional therapeutic agent, wherein the additional therapeutic agent is an ATR inhibitor, an AURK inhibitor or a CDK4/6 inhibitor.

### Claim 3

(canceled)

### Claim 4 (depends on 2)

The method of claim 2, wherein mRNA expression levels are detected via real-time quantitative PCR (qPCR), digital PCR (dPCR), Reverse transcriptase-PCR (RT-PCR), Northern blotting, microarray, dot or slot blots, in situ hybridization, or fluorescent in situ hybridization (FISH).

### Claim 5 (depends on 2)

The method of claim 2, wherein polypeptide expression levels are detected via Western blotting, enzyme-linked immunosorbent assays (ELISA), dot blotting, immunohistochemistry, immunofluorescence, immunoprecipitation, immunoelectrophoresis, or mass-spectrometry.

### Claim 6

A method for treating sarcoma in a patient in need thereof comprising administering to the patient an effective amount of tazemetostat and an effective amount of a CDK4/6 inhibitor, an AURK inhibitor or an ATR inhibitor.

### Claim 7 (depends on 2)

The method of claim 2, wherein the CDK4/6 inhibitor is selected from the group consisting of palbociclib, ribociclib, and abemaciclib.

### Claim 8 (depends on 2)

The method of claim 2, wherein the AURK inhibitor is a selective inhibitor of AURKB or a pan AURK inhibitor.

### Claim 9 (depends on 8)

The method of claim 8, wherein the AURK inhibitor is selected from the group consisting of tozasertib, SP-96, AT9283, danusertib (PHA-739358), AMG900, cenisertib, SNS-314, barasertib, hesperadin, AZD1152, GSK1070916, CYC116, BI 811283, AZD2811, PHA680632, reversine, CCT129202, CCT137690, S49076, PF-03814735, chiauranib, Alisertib, quercetin, and VX-680.

### Claim 10 (depends on 2)

The method of claim 2, wherein the ATR inhibitor is selected from the group consisting of elimusertib (BAY1895344), Schisandrin B, NU6027, dactolisib (NVP-BEZ235), EPT-46464, Torin 2, VE-821, AZ20, M4344 (VX-803), berzosertib (M6620 (VX-970)), and ceralasertib (AZD6738).

### Claim 11 (depends on 2)

The method of claim 2, wherein the patient is non-responsive to at least one prior line of cancer therapy.

### Claim 12 (depends on 11)

The method of claim 11, wherein the at least one prior line of cancer therapy is chemotherapy or immunotherapy.

### Claim 13 (depends on 2)

The method of claim 2, wherein the sarcoma is a rhabdoid sarcoma or an epithelioid sarcoma.

### Claim 14 (depends on 2)

The method of claim 2, wherein the sarcoma comprises a deficiency in a BAF chromatin remodeling complex component or SMARCB1.

### Claim 15 (depends on 2)

The method of claim 2, wherein the patient comprises an acquired mutation in EZH2, CDKN2A B, CDKN1A, ANKRD11 or RB1.

### Claim 16 (depends on 2)

The method of claim 2, wherein the patient exhibits acquired resistance or intrinsic resistance to tazemetostat.

### Claim 17 (depends on 2)

The method of claim 2, wherein the patient is a child or an adult.

### Claim 18 (depends on 2)

The method of claim 2, wherein the CDK4/6 inhibitor, the AURK inhibitor, or the ATR inhibitor is sequentially, simultaneously, or separately administered with tazemetostat.

### Claim 19 (depends on 2)

The method of claim 2, wherein the CDK4/6 inhibitor, the AURK inhibitor, the ATR inhibitor or tazemetostat is administered orally, intravenously, intramuscularly, intraperitoneally, or subcutaneously.

### Claim 20

(canceled)
